Your Biopsy Was Benign (Bethesda II): Your Next 5 Years of Surveillance
Written by John P. Sabra, MD FACS
Updated September 2026
Educational only. This article is not medical advice. Always consult your physician about your individual situation.
A Bethesda II result is the most common biopsy outcome and the one most patients hope for. It means the cells from the thyroid nodule needle biopsy are benign. The nodule is almost certainly not cancer. The next phase of care is no longer evaluation but surveillance. The question that follows is usually a practical one: what does the next five years look like?
Approximately 60 to 70% of all thyroid biopsies return a Bethesda II result. The malignancy risk associated with this category is not zero, but is less than 3%. A benign biopsy is one of the most reliable tests in thyroid medicine. False-negative rates are low, and the great majority of patients with a Bethesda II result will never develop thyroid cancer in that nodule.
The standard approach after a Bethesda II result is ultrasound surveillance, not biopsy repetition. The reason is that the cells have been examined and shown to be benign. The remaining concern is whether the nodule will change over time, which is monitored by serial ultrasound imaging rather than by repeat biopsy.
Surveillance Schedule by Ultrasound Risk
The surveillance interval depends on the original ultrasound risk category. Higher-risk-appearing nodules with a benign biopsy are watched somewhat more closely than lower-risk-appearing ones.
| TIRADS Risk Category | Recommended Surveillance Interval |
|---|---|
| TR1 or TR2 | Generally no further follow-up needed. |
| TR3 (mildly suspicious) with benign biopsy | Ultrasound at 24 months, then every 3 to 5 years if stable. |
| TR4 (moderately suspicious) with benign biopsy | Ultrasound at 12 to 24 months, then every 2 to 3 years if stable. |
| TR5 (highly suspicious) with benign biopsy | Ultrasound at 12 months, then annually for several years. Consider repeat biopsy if features evolve. |
⚕ Clinical note: The reason a highly suspicious nodule seen on ultrasound that then returns with a benign biopsy is still watched more closely, is that any biopsy has a small false-negative rate. When the ultrasound features remain highly suspicious despite a benign biopsy, the threshold for repeat sampling is lower than for nodules with low-suspicion ultrasound features. This is the principle: when the biopsy and the imaging disagree, the suspicious imaging is taken seriously.
What Counts as Significant Growth
One of the most important surveillance questions is what counts as significant growth of a nodule. Small variations in nodule size between ultrasounds are common and do not require action. The standard criteria for clinically significant growth, as defined by the American Thyroid Association, are an increase of at least 20% in two dimensions of the nodule, or an absolute increase of at least 2 mm in two dimensions, or a more than 50% increase in nodule volume.
Growth meeting these criteria warrants reassessment, typically with a repeat biopsy. Slow steady growth over many years often turns out to be a benign nodule continuing along the natural history of benign disease, but the repeat biopsy provides reassurance and detects the rare case in which the initial biopsy missed a small focus of cancer.
What Else Could Change the Plan
-
New suspicious features on follow-up ultrasound: Development of microcalcifications, an irregular margin, or hypoechoic appearance can prompt repeat biopsy even without significant growth.
-
Significant growth: Crossing the size thresholds above prompts repeat biopsy.
-
New symptoms: Pressure on the airway or esophagus, voice changes, or visible neck swelling warrants reassessment.
-
Suspicious lymph nodes: Any new lymph node abnormality on surveillance ultrasound is taken seriously and may prompt biopsy of the lymph node itself.
Treatment Options for Bethesda II Nodules
One useful consequence of a Bethesda II result is that non-surgical treatment options become reasonable for nodules that are causing symptoms or cosmetic concern. Radiofrequency ablation (RFA) is a well-established treatment for large benign thyroid nodules and is most appropriate after at least one (and often two) benign biopsies confirm the nodule is not malignant. Ethanol ablation is similarly an option for predominantly cystic benign nodules.
Surgery is also reasonable for benign nodules that are large, causing pressure symptoms, or producing too much thyroid hormone (a hot nodule).
The Bethesda II result is not a barrier to treatment when treatment is warranted. It simply removes cancer from the differential.
⚕ Clinical note A benign biopsy result is not a guarantee that the nodule will never need attention. It is a guarantee that, at the moment of biopsy, the cells were benign. Surveillance exists because nodules occasionally evolve over time. The point of imaging at intervals is to catch any change early, not because change is expected, but because it occasionally happens.
The Bottom Line
A Bethesda II result is the most common biopsy outcome and is associated with a very low risk of cancer. The next phase of care is ultrasound surveillance at intervals determined by the original ultrasound risk category. Most patients with a benign biopsy never need anything further beyond periodic imaging. Treatment options including RFA become reasonable for symptomatic benign nodules.
Schedule your follow-up ultrasound at the interval recommended for your category, and contact your physician sooner if you notice new neck swelling, voice changes, or pressure symptoms.
This article is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. Individual patient circumstances and clinical judgment determine the appropriate evaluation and management for every patient.
More from the Needle Biopsy (FNA) series
Ready to Talk to a Specialist?
A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.
Find a Thyroid Specialist Near You →